Skip to main content

Advertisement

Table 1 Summary of V H DJ H sequencing results

From: Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas

Pair number Sample ID Diagnosis/relapse Number of unique VHDJHrearrangements Number of unique VHDJHrearrangement per 103mapped reads Dominant VHDJHrearrangement Dominant rearrangement percentage Number of sub-clones (>10X) within dominant VHDJH Number of sub-clones (>10X) per 103dominant VHDJHalignments
1 1D Diagnosis 311 0.69 IGHV4-34 IGHD3-22 IGHJ5 96.9% 1,591 3.60
1R1 Relapse 265 0.50 IGHV4-34 IGHD3-22 IGHJ5 94.9% 2,109 4.07
1R2 Relapse NA NA NA NA NA NA
1R3 Relapse 396 0.66 IGHV4-34 IGHD3-22 IGHJ5 94.5% 2,487 4.26
2 2D Diagnosis 315 0.72 IGHV4-59 IGHD6-19 IGHJ5 82.2% 1,963 4.53
2R1 Relapse 3,131 7.27 IGHV4-59 IGHD6-19 IGHJ5 88.9% 1,372 3.44
2R2 Relapse NA NA NA NA NA NA
3 3D1 Diagnosis 950 1.84 IGHV3-49 IGHD2-8 IGHJ4 28.3% 421 2.81
IGHV3-49 IGHD3-22 IGHJ4 27.0% 596 2.13
3R2 Relapse 745 1.29 IGHV3-49 IGHD3-22 IGHJ4 29.2% 608 2.41
IGHV3-49 IGHD2-8 IGHJ4 28.0% 781 3.17
4 4D Diagnosis 9,158 23.08 IGHV3-7 IGHD4-17 IGHJ6 69.7% 1,318 4.75
4PR Progression 1,785 4.34 IGHV3-7 IGHD4-17 IGHJ6 43.0% 933 5.23
5 9D Diagnosis 2,911 4.27 IGHV4-34 IGHD6-13 IGHJ6 47.5% 1,381 4.16
IGHV1-18 IGHD6-13 IGHJ2 39.6% 1,075 3.96
9R Relapse 18,683 25.72 IGHV1-18 IGHD6-13 IGHJ2 9.2% 328 4.57
IGHV4-34 IGHD6-13 IGHJ6 3.5% 154 5.33
6 12D Diagnosis 7,570 22.12 IGHV3-74 IGHD4-17 IGHJ4 25.2% 0 0
12R Relapse 7,299 13.78 IGHV3-23 IGHD6-13 IGHJ4 24.1% 496 3.86
7 13D1 Diagnosis 7,931 27.09 IGHV3-23 IGHD3-9 IGHJ6 82.4% 870 5.14
13D2 Diagnosis 2,436 6.65 IGHV3-23 IGHD3-9 IGHJ6 89.6% 718 5.74
13R Relapse 1,204 3.71 IGHV3-23 IGHD3-9 IGHJ6 93.1% 858 5.27
8 14D Diagnosis 4,172 12.07 IGHV1-18 IGHD6-13 IGHJ2 48.0% 819 4.89
IGHV4-34 IGHD6-13 IGHJ6 24.1% 327 3.76
14R Relapse 1,206 3.84 IGHV1-18 IGHD6-13 IGHJ2 57.7% 883 4.81
IGHV4-34 IGHD6-13 IGHJ6 32.1% 421 3.96
9 15D1 Diagnosis 8,727 15.47 IGHV1-18 IGHD6-13 IGHJ2 23.7% 471 4.97
IGHV3-48 IGHD2-2 IGHJ4 26.8% 0 0
15D2 Diagnosis 955 2.83 IGHV1-18 IGHD6-13 IGHJ2 37.3% 18 2.73
IGHV4-34 IGHD6-13 IGHJ6 35.4% 0 0
15R Relapse 1,296 4.62 IGHV3-48 IGHD2-2 IGHJ4 37.1% 530 4.95
IGHV1-18 IGHD6-13 IGHJ2 33.5% 471 5.00
10 16D Diagnosis 11,303 12.10 IGHV1-18 IGHD6-13 IGHJ2 55.2% 867 1.61
16R Relapse 1,875 2.67 IGHV1-18 IGHD6-13 IGHJ2 44.8% 1,079 3.42
11 F6D Diagnosis 786 1.04 IGHV3-23 IGHD3-22 IGHJ4 72.5% 991 4.22
F6PR Progression 2,135 4.03 IGHV3-23 IGHD3-22 IGHJ4 61.0% 1,245 5.29
12 F7D Diagnosis 3,491 6.07 IGHV4-34 IGHD3-22 IGHJ6 45.2% 231 0.61
F7R Relapse 6,115 14.58 IGHV4-34 IGHD3-22 IGHJ6 40.0% 82 0.33
13 SPF6-1 Diagnosis 1,160 2.41 IGHV3-7 IGHD3-10 IGHJ4 90.0% 1,691 3.83
SPF6-2 Diagnosis 828 1.75 IGHV3-7 IGHD3-10 IGHJ4 93.1% 1,854 3.93
SPF6-3 Relapse 719 1.54 IGHV3-7 IGHD3-10 IGHJ4 95.8% 1,754 3.85
14 SPF10-1 Diagnosis 1,463 3.17 IGHV3-49 IGHD3-10 IGHJ5 67.8% 1,425 3.65
SPF10-2 Relapse 1,731 3.73 IGHV3-49 IGHD3-10 IGHJ5 30.2% 777 4.37
  1. NA, not available.